[(1R,3R,6S,7E,10S,11S,12E,16R,20R,22S)-10,20-dihydroxy-16-(hydroxymethyl)-12-(2-methoxy-2-oxoethylidene)-9,9-dimethyl-18-oxo-5,17,26,27,28-pentaoxatetracyclo[20.3.1.13,6.110,14]octacos-7-en-11-yl] octanoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: [(1R,3R,6S,7E,10S,11S,12E,16R,20R,22S)-10,20-dihydroxy-16-(hydroxymethyl)-12-(2-methoxy-2-oxoethylidene)-9,9-dimethyl-18-oxo-5,17,26,27,28-pentaoxatetracyclo[20.3.1.13,6.110,14]octacos-7-en-11-yl] octanoate
• 化学式: C₃₇H₅₈O₁₃
• 分子量: 710.8
• InChiKey: ZSBIIIBBYMYCRY-JZGVXZRASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  50
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  177
• 氢给体数：
  3
• 氢受体数：
  13

文献信息

• TREATMENT OF LATENT HIV INFECTION
  申请人：VOLPE Joseph M

  公开号：US20150320893A1

  公开（公告）日：2015-11-12

  Methods for treating HIV positive patients, and purging and eradicating latent HIV virus from a patient's system, are disclosed. The bulk of viral load is eradicated using conventional antiretroviral (ARV) therapy. Compounds that encourage viral production in the latent cells are then administered, preferably without activating those cells, while maintaining the ARV therapy. The administration of compounds that encourage viral production in latent cells is cycled, and after around 7-10 cycles, the methods can virtually eliminate latent HIV in the patient. Ideally, the ARV regimen includes at least one integrase inhibitor, at least one entry inhibitor, such as a CCR5 antagonist, and at least one, and preferably two, reverse transcriptase inhibitors. The compounds that encourage viral production in latent cells ideally include a combination of prostratin or a prostratin analog and an HDAC inhibitor, such as butyrate, valproate, or SAHA.
• US8735609B2
  申请人：——

  公开号：US8735609B2

  公开（公告）日：2014-05-27